Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2

Hematology/Oncology Clinics of North America

Volumn 17, Issue 6, 2003, Pages 1435-1448

  Rook, Alain H ^a   Kuzel, Timothy M ^b   Olsen, Elise A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ALPHA INTERFERON; BETA INTERFERON; BEXAROTENE; CHLORMETHINE; CYTOKINE; CYTOTOXIC AGENT; ETRETIN; ETRETINATE; FLUDARABINE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; ISOTRETINOIN; OPIATE ANTAGONIST; PEGINTERFERON; PEGINTERFERON ALPHA; PENTOSTATIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 12; RETINOID; UNCLASSIFIED DRUG; VINBLASTINE;

ACUTE TOXICITY; ANOREXIA; ARTHRALGIA; BITTER TASTE; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER RADIOTHERAPY; CHILL; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; COUGHING; CUTANEOUS T CELL LYMPHOMA; DEFECATION DISORDER; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELEVATED LIVER ENZYME; FATIGUE; FEVER; FLU LIKE SYNDROME; FREQUENT STOOL; HAIR LOSS; HEADACHE; HUMAN; HYPOTHALAMUS DISEASE; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; IMPOTENCE; INJECTION SITE REACTION; LEUKOPENIA; LIBIDO DISORDER; LIVER FUNCTION TEST; LOOSE FECES; MALAISE; MEMORY DISORDER; METALLIC TASTE; MOTOR DYSFUNCTION; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NEUROENDOCRINE DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; PUVA; REVIEW; SATIETY; SEXUAL FUNCTION; SEZARY SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; TASTE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 0346996938     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00109-6     Document Type: Review

References (66)

1. Rook AH, Vowels BR, Jaworsky C, et al. The immunopathogenesis of cutaneous T-cell lymphoma:Abnormal cytokine production by Sezary T cells. Arch Dermatol 1993;129:486-9.
2. Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002;100:3287-94.
3. Vowels BR, Cassin M, Vonderheid E, et al. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-4.
4. Asadullah K, Docke WD, Haeussler A, et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996;107:833-7.
5. Hoppe RT, Medeiros LJ, Warnke RA, et al. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.
6. Vermeer MH, van Doorn R, Dukers D, et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001;19:4322-9.
7. Asadullah K, Friedrich M, Docke WD, et al. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early cutaneous T-cell lymphoma. J Invest Dermatol 1997;108:743-7.
8. Berger CL, Wang N, Christensen I, et al. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996;107:392-7.
9. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 Therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.
10. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin N Amer 1995;9:1089-107.
11. Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med 1986;81:871-82.
12. Koeller JM. Biologic response modifiers. The interferon alfa experience. Am J Hosp Pharm 1989;46(Suppl 2):511-5.
13. Physicians' Desk Reference. 57th edition. Montvale (NJ): Medical Economics, Inc.; 2003.
14. Bunn PA, Foon KA, Inde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-7.
15. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:395-407.
16. Papa G, Tura S, Mandelli F, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment choice? Br J Haematol 1991;79(Suppl 1):48-51.
17. Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-α2a alone and in combination with etretinate. Br J Dermatol 1988;118:811-8.
18. Tura S, Mazzer P, Zinzanai PL, et al. Alpha recombinant interferon in the treatment of mycosis fungoides. Haematologica 1987;72:337-40.
19. Springer EA, Kuzel TM, Varakojis D, et al. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. J Am Acad Dermatol 1993;29:42-6.
20. Vonderheid EC, Thompson R, Smiles KA, et al. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Arch Dermatol 1977;113:454-62.
21. Wolff JM, Zotelli JA, Rabin BS, et al. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985;13:604-12.
22. Ross C, Tingsgaard P, Thomsen K, et al. Pretreatment circulating IFN-neutralizing immunoglobulins to IFN-α and their possible influence in the clinical response to interferon treatment in patients with cutaneous T-cell lymphoma. J Interferon Res 1992;12(Suppl 1):5165.
23. Figlin RA, Itri LM. Anti-interferon antibodies. A perspective. Semin Hematol 1988;25(Suppl 3): 9-15.
24. Itri LM, Sherman MI, Palleroni AV. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-α2a. J Interferon Res 1989;9(Suppl 1):S9-15.
25. Steis RG, Smith II JW, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. J Eng J Med 1988;318:1409-13.
26. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995;13:257-63.
27. Borden EC, Parkinson D. Interferons: effectiveness, toxicities and cost. Ann Intern Med 1996;125:614-6.
28. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
29. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-α. Clin Exp Immunol 1992;90:363-7.
30. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403.
31. Kuriyama K, Hori T, Mori T, et al. Actions of interferon-α and interleukin-1β on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res Bull 1990;24:803-10.
32. Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neurobiological defects associated with interferon alfa therapy for leukemia. Neurology 1995;45:947-50.
33. Kirkwood JM, Ernstaff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984;2:336-52.
34. Kuzel TM, Gilym K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:203-7.
35. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995;13:561-6.
36. Mostow EN, Neckel RN, Oberhelman L, et al. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993;129:747-52.
37. Otte H-G, Herges A, Stadler R. Kombinations therapie mit interferon alfa-2a und PUVA bei kutenen T-zell lymphomen. Hautarzt 1992;43:695-9.
38. Stadler R, Otte H-G, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-α2a plus acitretin versus interferon-α2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578-81.
39. Rook AH, Prystowsky MB, Cassin M, et al. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch Dermatol 1991;127: 1535-40.
40. Fritz TM, Kleinhans M, Nestle FO, et al. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome. Br J Dermatol 1999; 140:1144-7.
41. Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001;44:253-60.
42. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996;35:946-57.
43. Fimiani M, Rubegni P, DeAloe G, et al. Role of extracorporeal photochemotherapy alone or in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1999;41:502-3.
44. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-86.
45. Foss FM, Ihde DC, Breneman DL, et al. Phase II study ofpentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1992;10:1907-13.
46. Foss F, lhde DC, Phelps R, et al. Phase II study of fludarabine and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome [abstract]. Proc Am Soc Clin Oncol 1992;11A:1065.
47. Bernard S, Gill P, Rosen P, et al. A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies. Med Pediatr Oncol 1991;19:276-82.
48. Scheulen ME, Ohl S, Bamberg M, et al. Treatment of mycosis fungoides by recombinant leucocyte alpha-A interferon and vinblastine. J Cancer Res Clin Oncol 1986;111:540.
49. Zinzani PL, Mazza P, Gherlinzoni F. Beta interferon in the treatment of mycosis fungoides. Haematologica 1988;73(6):547-8.
50. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferonγ for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:208-12.
51. Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome: regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 2001;44:28-32.
52. Platsoucas CD, Fox FE, Oleszak E, et al. Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Research 1989;9:849-58.
53. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. Bio Drugs 2001;15:419-29.
54. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
55. Rook AH, Kubin M, Cassin M, et al. Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995;154:1491-8.
56. Wang KS, Zorn E, Ritz J. Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood 2001;97(12):3860-6.
57. Malek TR, Gutgsell NS. IL-2 and its receptor: structure, function, and regulation of expression. In: Atkins MW, Mier JW, editors. Therapeutic applications of interleukin-2. New York: Marcel Dekker; 1993. p. 3-25.
58. Boldt DH, Ellis TM. Biologic effects of interleukin-2 administration on the immune system. In: Atkins MW, Mier JW, editors. Therapeutic applications of interleukin-2. New York: Marcel Dekker; 1993. p. 73-91.
59. Benyunes MC, Fefer A. Interleukin-2 in the treatment of hematologic malignancies. In: Atkins JW, Mier JW, editors. Therapeutic applications of interleukin-2. New York: Marcel Dekker; 1993. p. 163-75.
60. Nagatani T, Kin S, Baba N, et al. A case of cutaneous T-cell lymphoma treated with recombinant interleukin-2 (IL-2). Acta Derm Venereol 1988;68:504-8.
61. Marolleau JP, Baccard M, Flageul B, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.
62. Baccard M, Marolleau JP, Bybojad M. Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant intereukin-2 [letter]. Arch Dermatol 1997;133:656.
63. Beun GDM, Vlasveld LT, Bot F, et al. Low-dose rIL-2-induced remission of disseminated CD30+ anaplastic large-cell lymphoma through reinforcement of presumed T-cell-mediated tumor cell killing, complicated by unilateral drowning of lymphoma-infiltrated lung. J Immunother 1996;19:162-7.
64. Gold PJ, Thompson JA, Lindgren C, et al. Phase I trial of subcutaneous, outpatient interleukin-2 for patients with advanced mycosis fungoides [abstract]. Blood 1996;88:191.
65. Rook AH, Zaki MH, Wysocka M, et al. IL-12 therapy of CTCL. Ann N Y Acad Sci 2001;941:177-84.
66. Meech SJ, Edelson R, Walsh P, et al. Reversible resistance to apoptosis in cutaneous T-cell lymphoma. Ann N Y Acad Sci 2001;941:46-58.